期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

甲状腺相关性眼病与^(99m)Tc-生长抑素类似物眼眶显像

下载PDF
导出
摘要 甲状腺相关性眼病(TAO)被认为是一种与甲状腺疾病相关的器官特异性的自身免疫性疾病,其具体发病机制不清,这给临床早期诊断及治疗带来极大困难。本文从TAO的发病,临床分期及生长抑素类似物核素显像在TAO中的应用作一综述。
作者 张朝霞 孙斌
机构地区 山西医科大学第三医院眼科
出处 《国外医学（眼科学分册）》 2005年第4期270-274,共5页 Foreign Medical Sciences(Section of Ophthalmology )
关键词 甲状腺相关性眼病/病因学 生长抑素/类似物和衍生物 眼眶/放射性核素显像 甲状腺相关性眼病 生长抑素类似物 核素显像 自身免疫性疾病 眼眶 发病机制 临床分期
分类号 R581 [医药卫生—内分泌]
  • 相关文献

参考文献25

  • 1Monaco F.Classification of thyroid diseases:suggestions for a revision.J Clin Endocrinol Metab,2003,88:1428-1432.
  • 2Tallstedt L,Norberg R.Immunohistochemical staining of normal and Graves'extraocular muscle.Invest Ophthalmol Vis Sci,1988,29:175-184.
  • 3Hufnagel TJ,Hickey WF,Cobbs WH,et al.Immunohistochemical and ultrastructural studies on the exenterated orbital tissues of a patient with Graves'disease.Ophthalmology,1984,91:1411-1419.
  • 4Aniszewski JP,Valyasevi RW,Bahn RS.Relationship between disease duration and predominant orbital T cell subset in Graves'ophthalmopathy.J Clin Endocrinol Metab,2000,85:776-780.
  • 5Natt N,Bahn RS.Cytokines in the evolution of Graves'ophthalmopathy.Autoimmunity,1997,26:129-136.
  • 6Pappa A,Lawson JM,Calder V,et al.T cells and fibroblasts in affected extraocular muscles in early and late thyroid associated ophthalmopathy.Br J Ophthalmol,2000,84:517-522.
  • 7Prabhakar BS,Bahn RS,Smith TJ.Current perspective on the pathogenesis of Graves'disease and Graves'ophthalmopathy.Endocr Rev,2003,24:802-835.
  • 8Gerding MN,van der Meer JW,Broenink M,et al.Association of thyrotrophin receptor antibodies with the clinical features of Graves'ophthalmopathy.Clin Endocrinol(Oxf),2000,52:267-271.
  • 9Werner SC.Modification of the classification of the eye changes of Graves'disease.Am J Ophthalmol,1977,83:725-727.
  • 10Bartalena L,Pinchera A,Marcocci C.Management of Graves'ophthalmopathy:reality and perspectives.Endocr Rev,2000,21:168-199.

二级参考文献10

  • 1Durak I, Durak H, Erign M, et al. Somatostatin receptors in the orbits[J]. Clin Nucl Med, 1995,20:237-242.
  • 2Ozata M, Bolu E, Sengul A, et al. Effects of octreotide treatment on Graves' ophthalmopathy and circulating sI- CAM-1 levels[J] .Thyroid,1996,6:283-288.
  • 3Krassas G E, Dumas A, Pontikides N, et al. Somatostatin receptor scintigraphy and octreotide treatment in patients with thyroid eye disease [J]. Clin Endocrinol, 1995,42: 571-580.
  • 4Kung A W C, Michon J, Tai K S, et al. The effect of somatostatin versus corticosteroid in the treatment of Graves' ophthalmopathy [J]. Thyroid, 1996,6: 318-324.
  • 5Krassas G E, Kaltsas T, Dumas A, et al. Lanreotide in the treatment of patients with thyroid eye disease[J]. Eur J Endocrinol, 1997,136: 416-422.
  • 6Krassas G E, Doumas A, Kaltsas T, et al. Somatostatin receptors scintigraphy before and after treatment with somatostatin analogues in patients with thyroid eye disease [J].Thyroid, 1999,9: 47-52.
  • 7Uysal A R, Corapcioglu D, Tonyukuk V C, et al. Effects of octreotide treatment on Graves' ophthalmopathy [J]. Endocrinol J, 1999,46: 573-577.
  • 8Heufelder A E. Somatostatin analogues in Graves' ophthalmopathy[J] .J Endocrinol Invest, 1997,20 (suppl to no 7):50-52.
  • 9Krassas G E. Somatostatin analogues in the treatment of thyroid eye disease [J]. Thyroid, 1998,8: 443-445.
  • 10Pasquali D, Vassallo P, Esposito D, et al. Somatostatin receptors gene expression and inhibitory effects of octreotide on primary cultures of orbital fibroblasts from Graves' ophthalmopathy[J]. J Mol Endocrinol, 2000,25: 63-71.

共引文献7

国外医学（眼科学分册）
2005年 第4期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部